We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate‐to‐severe plaque psoriasis naïve to systemic treatment.
- Authors
Leutz, A.; Pinter, A.; Thaçi, D.; Augustin, M.; Schuster, C.; Fotiou, K.; Hundemer, H.P.; Saure, D.; Mrowietz, U.; Reich, K.
- Abstract
Dear Editor, Psoriasis is a chronic inflammatory skin disorder, which, in cases of moderate-to-severe disease, requires long-term systemic therapy.1 For patients with an inadequate response or intolerance to a specific systemic therapy, switching psoriasis treatments is a common practice that may improve outcomes. At week 24, 19 (83%) patients receiving FAE and 31 (63%) patients receiving MTX switched to ixekizumab, while 48 (98%) patients receiving ixekizumab continued treatment. Efficacy and safety of ixekizumab after switching from fumaric acid esters or methotrexate in patients with moderate-to-severe plaque psoriasis naïve to systemic treatment.
- Subjects
DRUG efficacy; FUMARATES; METHOTREXATE; PSORIASIS; GINGIVITIS
- Publication
British Journal of Dermatology, 2021, Vol 184, Issue 3, p548
- ISSN
0007-0963
- Publication type
Article
- DOI
10.1111/bjd.19558